Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Polyp Recurrence Prevention
IRCT20151123025202N52Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of omalizumab in allergic fungal rhinosinusitis (AFRS) and chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Hamadan University of Medical Sciences. Started Mar 2026; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic fungal rhinosinusitis (AFRS)chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on IRCT20151123025202N52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151123025202N52.